# Bliss GVS Pharma (NSE: BLISSGVS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/BLISSGVS · Pivot · prices to 22 Oct 2026

Bliss GVS Pharma (NSE: BLISSGVS) closed at ₹638.00 on 22 Oct 2026, up 2.42% on the day. With a market capitalisation of ₹6,766 Cr, it ranks 674th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 53.1× trailing earnings, against a return on equity of 10.8% in FY26. Over the past year the share price has risen 319.4%. Its 52-week range is ₹118.00 (10 Nov 2025) to ₹739.90 (28 Sep 2026); the last close is 13.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹257 Cr (+29.8% year on year) and net profit ₹37 Cr (+122.2%), on a consolidated basis. Promoters held 35.01% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹638.00 |
| Market cap | ₹6,766 Cr |
| P/E (trailing) | 53.1 |
| ROE | 10.8% (FY26) |
| ROCE | 16.2% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹739.90 (28 Sep 2026) |
| 52-week low | ₹118.00 (10 Nov 2025) |
| 1-year return | +319.4% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹257 Cr | +29.8% | ₹37 Cr | +122.2% | ₹3.37 |
| Q3 FY26 | ₹218 Cr | +3.7% | ₹25 Cr | −4.0% | ₹2.20 |
| Q2 FY26 | ₹244 Cr | +12.3% | ₹29 Cr | +11.3% | ₹2.58 |
| Q1 FY26 | ₹207 Cr | +13.0% | ₹44 Cr | +100.6% | ₹4.08 |
| Q4 FY25 | ₹198 Cr | −0.1% | ₹17 Cr | — | ₹1.47 |
| Q3 FY25 | ₹210 Cr | +4.8% | ₹26 Cr | −11.2% | ₹2.27 |
| Q2 FY25 | ₹218 Cr | +2.7% | ₹26 Cr | −40.3% | ₹2.31 |
| Q1 FY25 | ₹184 Cr | +15.1% | ₹22 Cr | +53.9% | ₹1.97 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹810 Cr | ₹90 Cr |
| FY24 | ₹770 Cr | ₹82 Cr |
| FY23 | ₹752 Cr | ₹77 Cr |
| FY22 | ₹747 Cr | ₹23 Cr |
| FY21 | ₹577 Cr | ₹74 Cr |
| FY20 | ₹689 Cr | ₹95 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 35.01%
- Foreign institutions: 8.07%
- Domestic institutions: 9.47%
- Non-institutions: 47.45%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Thyrocare Technologies](https://app.pivotnow.in/stock/THYROCARE) | ₹470.65 | ₹7,491 Cr | 46.2 | — |
| [Morepen Laboratories](https://app.pivotnow.in/stock/MOREPENLAB) | ₹125.70 | ₹6,888 Cr | 72.7 | — |
| [Supriya Lifescience](https://app.pivotnow.in/stock/SUPRIYA) | ₹848.80 | ₹6,831 Cr | 32.7 | — |
| [Sanofi India](https://app.pivotnow.in/stock/SANOFI) | ₹2,845.00 | ₹6,552 Cr | 21.2 | — |
| [Entero Healthcare Solutions](https://app.pivotnow.in/stock/ENTERO) | ₹1,504.20 | ₹6,547 Cr | 57.1 | — |
| [Kovai Medical Center & Hospital](https://app.pivotnow.in/stock/KOVAI) | ₹5,738.00 | ₹6,279 Cr | 25.7 | — |

## Questions and answers

### What is the share price of Bliss GVS Pharma today?

Bliss GVS Pharma (NSE: BLISSGVS) last closed at ₹638.00 on 22 Oct 2026. Its 52-week high is ₹739.90 and its 52-week low is ₹118.00.

### What is the market cap of Bliss GVS Pharma?

Bliss GVS Pharma's market capitalisation is ₹6,766 Cr (₹6,766 Cr) at the 22 Oct 2026 close, ranking 674th among the NSE companies Pivot tracks.

### What is the P/E ratio of Bliss GVS Pharma?

Bliss GVS Pharma trades at a trailing P/E of 53.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.2.

### What is the ROE and ROCE of Bliss GVS Pharma?

Return on equity was 10.8% in FY26 and return on capital employed was 16.2% in FY26 (consolidated figures).

### Is Bliss GVS Pharma a debt-free company?

Bliss GVS Pharma is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Bliss GVS Pharma's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Bliss GVS Pharma reported revenue of ₹257 Cr, +29.8% year on year, and net profit of ₹37 Cr, +122.2% year on year.

### How has Bliss GVS Pharma stock performed over the last year?

Bliss GVS Pharma's share price has risen 319.4% over the past year, +42.7% over three months and −3.8% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Bliss GVS Pharma?

As of 30 Jun 2026: promoters 35.01%, foreign institutions 8.07%, domestic institutions 9.47%, non-institutions 47.45%.

### Who are Bliss GVS Pharma's competitors?

The listed Pharma & Healthcare companies closest to Bliss GVS Pharma by market cap are Thyrocare Technologies, Morepen Laboratories, Supriya Lifescience, Sanofi India, Entero Healthcare Solutions and Kovai Medical Center & Hospital.

### Is Bliss GVS Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Bliss GVS Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BLISSGVS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.